Recipharm AB (STO:RECIB), a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry, reported on Wednesday the decision by its board of directors to withdraw the previously communicated dividend proposal of SEK1.60 per share and the new proposal to the Annual General Meeting, of 12 May 2020, that no dividend be paid.
Reportedly, the outbreak of COVID-19 and the extraordinary measures and recommendations that authorities and governments have taken to reduce the spread of the coronavirus have significantly affected operating conditions on the markets where Recipharm operates. Accordingly, the board has decided to withdraw the dividend.
According to the company, given the rapid development of the spread of COVID-19 and the high level of uncertainty currently present, it is too early to quantify the potential impact on its operations and results. This decision does not constitute a change in Recipharm's long-term dividend policy or future ambitions for dividend, the company clarified.
(EUR1.00=SEK10.94)
Swissmedic Approves Carbetocin Ferring for the Prevention of Postpartum Haemorrhage in All Births
Mylan collaborates with Gilead Sciences for remdesivir distribution
Mylan to distribute investigational antiviral remdesivir for the potential treatment of COVID-19
Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19
Verato Launches Verato Enrich to Accelerate COVID-19 Response
Lannett Company reports third quarter fiscal 2020 financial results
Eli Lilly and Company's board approves USD0.74 per share dividend for Q2 2020
Eli Lilly announces Q2 dividend
Bio-Rad Receives FDA Emergency Use Authorization for Droplet Digital PCR SARS-CoV-2 Test Kit